Drug evaluation: Lymphoseek - Neoprobe's sentinel lymph node imaging agent for use in cancer patients

Curr Opin Investig Drugs. 2006 Dec;7(12):1100-7.


Neoprobe, under license from the University of California San Diego Cancer Center, is developing 99mTc-DTPA-mannosyl-dextran (Lymphoseek) as a potential agent for imaging lymph nodes in patients undergoing treatment for breast cancer and melanoma. Phase II trials of Lymphoseek were initiated in mid 2006.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Contrast Media / adverse effects
  • Contrast Media / pharmacokinetics*
  • Drug Evaluation, Preclinical
  • Humans
  • Sentinel Lymph Node Biopsy / methods*
  • Structure-Activity Relationship


  • Contrast Media